Učitavanje...
Emerging agents for the treatment of metastatic urothelial cancer
Over the past few decades, platinum-based combination chemotherapy (PBCC) has been the preferred initial therapy for metastatic urothelial cancer (mUC). However, despite a response rate of approximately 50%, a small proportion of patients with distant metastases may be cured by cisplatin-based combi...
Spremljeno u:
| Izdano u: | Investig Clin Urol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The Korean Urological Association
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100010/ https://ncbi.nlm.nih.gov/pubmed/33943047 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.20200597 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|